GeoVax Archives - Business RadioX ®

SIMON SAYS, LET’S TALK BUSINESS: David Dodd with GeoVax

January 19, 2023 by Mike

Gwinnett Studio

SIMON SAYS, LET'S TALK BUSINESS: David Dodd with GeoVax

00:00 /

David Dodd/GeoVax

GeoVax Labs is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease program includes GEO-CM04S1, a next-generation Covid-19 vaccine designed for the growing population of high-risk immunocompromised patients with cancers, autoimmune conditions, and neuromuscular diseases. Currently in two Phase 2 clinical trials, CM04S1 is being evaluated as a Covid-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient. In addition, CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. A synergistic program is underway with the rights from the US NIH to make GeoVax the first U.S. supplier of the vaccine vector MVA for protection against Monkeypox and Smallpox. GEO-CM04S1 GeoVax has a solid financial foundation, is listed on Nasdaq (“GOVX”), with a leadership team who have driven significant value creation across multiple life science companies over the past several decades.

Mark Koski with NFHS Network and Michael Hellerstein with GeoVax, Inc.

July 19, 2018 by angishields

Atlanta Business Radio

Mark Koski with NFHS Network and Michael Hellerstein with GeoVax, Inc.

00:00 /

Mark Koski was announced as the Chief Executive Officer for the NFHS Network on September 1, 2017 after serving as the NFHS Director of Sports, Events and Development since he joined the staff in 2007. As the NFHS Network CEO, Koski is responsible for directing a team that delivers more than 50,000 live games per year on NFHSNetwork.com, via desktop, mobile and TV through its Apple TV app. The NFHS Network is the nation’s leader in live high school sports and activities. Koski also serves as the NFHS Director of Marketing and oversees the NFHS national #MyReasonWhy and #BecomeAnOfficial campaigns as well as the events and marketing departments. Prior to joining the NFHS, he was an Assistant Director at the New Mexico Activities Association and teacher and varsity football and track & field coach at 6A Manzano High School in Albuquerque, New Mexico. Koski earned his bachelor’s in physical education and master’s degree in sport administration from the University of New Mexico. While an undergraduate, he was a decathlete and 400-meter sprinter for the Lobo track and field team. He is in his final stages of earning his Ed.D. in Education.

Follow the NFHS Network on Facebook, LinkedIn, and Twitter.

Michael Hellerstein serves as Director of Regulatory Affairs and Quality Systems at GeoVax, a clinical-stage biotechnology company developing vaccines against infectious diseases and cancers. Initially trained as a molecular biologist, Mr. Hellerstein joined GeoVax in 2005 and has progressively expanded his job responsibilities. He has managed quality control since 2006, quality systems since 2007, outsourced manufacturing since 2008, regulatory affairs since 2014, and project management and government contracting since 2015. Prior to joining GeoVax in 2005, Mr. Hellerstein worked at several companies including Pfizer, Cell Signaling Technology, and Blue Sky Biotech, which he co-founded. Mr. Hellerstein obtained his A.B. in biology from Harvard University in 1999.

Fighting Infections

July 6, 2015 by angishields

Health Connect South

Fighting Infections

00:00 /

GeoVax — Debora Carrier, Michael Hellerstein, Jay Schafer

Fighting Infections

This week we hosted two experts whose companies are fighting infections from different directions. Michael Hellerstein is the Director of Regulatory Affairs and Quality Systems for GeoVax. They’re a biotechnology company that’s developing vaccines for Ebola and HIV.

Debora Carrier combined her experience as a fashion model and a healthcare provider to think of a better-looking scrub uniform that is both better looking and resistant to spreading infections. She founded Twice As Nice Uniforms to give health workers and physicians a more visually appealing choice while at the same time helping reduce the alarming rate of infections acquired in health delivery environments.

Michael talked about how GeoVax has been fighting infections through innovative approaches to vaccine development, utilizing vaccine-like particles to tackle HIV and more recently, Ebola. He shared how prevalent HIV remains today and that more work is being focused on treating the disease versus developing vaccines to prevent it.

He shared how technology has evolved that allows biotech companies to identify genetic components to viruses, which enables them to incorporate pieces of this material and instill it into a harmless organism. Then, as the organism reproduces, it produces a copy of itself that has some characteristics of the pathogen the vaccine is designed to fight. This “recombinant” vaccine doesn’t make the body sick but it does prompt an immune response from the body against the pathogenic virus, providing protection against infection.

GeoVax is able to create particles that are safer to use than vaccines that contain live pathogen, allowing people who may have some immune compromise to get some protection as well in some cases.

The company has used this technology to get a vaccine that is showing some promise for preventing HIV infection. Michael talked about how the clinical trials are progressing and how long it takes to get a vaccine approved for use in people versus the time it takes to develop a medication to treat disease.

Debora talked about her story as a healthcare provider for over 20 years led her to think of a scrub design that looks much better than the bulky, wrinkle-prone scrubs the health community has been using for decades. She talked about how frequently the environment is very cool, prompting workers to wear long sleeves and/or jackets while delivering care.

We discussed how long sleeves prevent washing the lower arms as is recommended and how the fabric can readily carry bacteria and viral material from one patient to another. Debora investigated various athletic materials that can help regulate body temperature in various climes, while at the same time possessing antimicrobial properties.

Twice As Nice Uniforms utilize an American-made material that controls moisture and uses a scrub design that incorporates a removable liner that allows the worker to be comfortable when the rooms are very cool.

In looking at the design of the garments, it’s clear she brought her experience in modeling to bear in the style/cut of the uniforms they’re creating.

Special Guests:

Debora Carrier, CEO/Founder of Twice As Nice Uniforms